Wire · opportunities
FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 September 2026 · Fusion42 review
The FDA approved lirafugratinib for adult patients with previously treated, unresectable or metastatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement, based on results from the REFOCUS phase 2 trial demonstrating a 46% objective response rate and median duration of response of 11.8 months. The approval includes safety guidelines addressing ocular toxicity, hyperphosphatemia, and embryo-fetal risks with a recommended dosing of 70 mg daily.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
You now have a new regulatory-approved treatment path for FGFR2+ cholangiocarcinoma. Oncology startups working in targeted therapies should consider partnerships or trials leveraging this approval to fast-track patient impact.
◆ Coverage
10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026
◆ Topics